Annesha C. King
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Annesha C. King has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
Efrain Rodriguez
Center for Neurodegeneration and Experimental Therapeutics, University of Alabama 2 Department of Neurology , at Birmingham, Birmingham, AL 35294
1 shared publicationEmily Payne
Center for Neurodegeneration and Experimental Therapeutics, University of Alabama 2 Department of Neurology , at Birmingham, Birmingham, AL 35294
1 shared publicationEmily Stephens
Center for Neurodegeneration and Experimental Therapeutics, University of Alabama 2 Department of Neurology , at Birmingham, Birmingham, AL 35294
1 shared publicationJahmel A. Fowler
Center for Neurodegeneration and Experimental Therapeutics, University of Alabama 2 Department of Neurology , at Birmingham, Birmingham, AL 35294
1 shared publicationJoshua J. White
Department of Pathology & Immunology, 1250 Moursund Street, Suite 1325, Houston, TX 77030, USA; Department of Neuroscience, 1250 Moursund Street, Suite 1325, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute of Texas Children's Hospital, 1250 Moursund Street, Suite 1325, Houston, TX 77030, USA
1 shared publicationLauren N. Miterko
Program in Developmental Biology, Baylor College of Medicine, 1250 Moursund Street, Suite 1325, Houston, TX 77030, USA; Jan and Dan Duncan Neurological Research Institute of Texas Children's Hospital, 1250 Moursund Street, Suite 1325, Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
- 1 November 2024
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 17 (11)
Modulation of SNARE-dependent exocytosis in astrocytes improves neuropathology in Huntington's disease
Huntington's disease (HD) is a fatal, progressive neurodegenerative disorder. Prior studies revealed an increase in extracellular glutamate levels after evoking astrocytic SNARE-dependent exocytosis from cultured primary astrocytes from mutant huntingtin (mHTT)-expressing BACHD mice compared to control astrocytes, suggesting alterations in astrocytic SNARE-dependent exocytosis in HD. We used BACHD and dominant-negative (dn)SNARE mice to decrease SNARE-dependent exocytosis from astrocytes to determine whether reducing SNARE-dependent exocytosis from astrocytes could rescue neuropathological changes in vivo. We observed significant protection against striatal atrophy and no significant rescue of cortical atrophy in BACHD/dnSNARE mice compared to BACHD mice. Amino acid transporters are important for modulating the levels of extracellular neurotransmitters. BACHD mice had no change in GLT1 expression, decreased striatal GAT1 expression and increased levels of GAT3. There was no change in GAT1 after reducing astrocytic SNARE-dependent exocytosis, and increased GAT3 expression in BACHD mice was normalized in BACHD/dnSNARE mice. Thus, modulation of astrocytic SNARE-dependent exocytosis in BACHD mice is protective against striatal atrophy and modulates GABA transporter expression.
- 1 November 2024
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 17 (11)
Open AccessModulation of SNARE-dependent exocytosis in astrocytes improves neuropathology in Huntington's disease
Huntington's disease (HD) is a fatal, progressive neurodegenerative disorder. Prior studies revealed an increase in extracellular glutamate levels after evoking astrocytic SNARE-dependent exocytosis from cultured primary astrocytes from mutant huntingtin (mHTT)-expressing BACHD mice compared to control astrocytes, suggesting alterations in astrocytic SNARE-dependent exocytosis in HD. We used BACHD and dominant-negative (dn)SNARE mice to decrease SNARE-dependent exocytosis from astrocytes to determine whether reducing SNARE-dependent exocytosis from astrocytes could rescue neuropathological changes in vivo. We observed significant protection against striatal atrophy and no significant rescue of cortical atrophy in BACHD/dnSNARE mice compared to BACHD mice. Amino acid transporters are important for modulating the levels of extracellular neurotransmitters. BACHD mice had no change in GLT1 expression, decreased striatal GAT1 expression and increased levels of GAT3. There was no change in GAT1 after reducing astrocytic SNARE-dependent exocytosis, and increased GAT3 expression in BACHD mice was normalized in BACHD/dnSNARE mice. Thus, modulation of astrocytic SNARE-dependent exocytosis in BACHD mice is protective against striatal atrophy and modulates GABA transporter expression.
- 1 February 2016
- Published by Elsevier in Neurobiology of Disease
- Vol. 86, 86-98
Pathogenesis of severe ataxia and tremor without the typical signs of neurodegeneration
- 1 February 2016
- Published by Elsevier in Neurobiology of Disease
- Vol. 86, 86-98
Pathogenesis of severe ataxia and tremor without the typical signs of neurodegeneration